| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,187,235 | 1 | 4 |
Sells | $42,242,344 | 26 | 96 |
| JOHNSON DAVID EDWARD | director | 1 | $1.19M | 0 | $0 | $1.19M |
| Eckhardt Sue Gail | director | 0 | $0 | 2 | $660,828 | $-660,828 |
| Freire Maria C | director | 0 | $0 | 1 | $949,164 | $-949,164 |
| Hefti Brenda | SVP and General Counsel | 0 | $0 | 2 | $1.15M | $-1.15M |
| Oliver Bob | director | 0 | $0 | 1 | $1.33M | $-1.33M |
| Beckerle Mary C | director | 0 | $0 | 3 | $1.93M | $-1.93M |
| POSTE GEORGE | director | 0 | $0 | 1 | $2.74M | $-2.74M |
| PAPADOPOULOS STELIOS | director | 0 | $0 | 1 | $4.36M | $-4.36M |
| Senner Christopher J. | EVP and CFO | 0 | $0 | 3 | $4.56M | $-4.56M |
| WYSZOMIERSKI JACK L | director | 0 | $0 | 2 | $4.58M | $-4.58M |
| Smith Julie | director | 0 | $0 | 2 | $4.69M | $-4.69M |
| Haley Patrick J. | EVP, Commercial | 0 | $0 | 4 | $7.6M | $-7.6M |
| Aftab Dana | EVP, Research and Development | 0 | $0 | 4 | $7.7M | $-7.7M |
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from …
Over the last 12 months, insiders at Exelixis, Inc. have bought $1.19M and sold $42.24M worth of Exelixis, Inc. stock.
On average, over the past 5 years, insiders at Exelixis, Inc. have bought $8.23M and sold $24.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: JOHNSON DAVID EDWARD (director) — $1.19M.
The last purchase of 27,532 shares for transaction amount of $1.19M was made by JOHNSON DAVID EDWARD (director) on 2025‑11‑25.
| 2026-08-10 | Sale | Beckerle Mary C | director | 9,812 0.004% | $53.66 | $526,512 | +10.17% | |
| 2026-06-01 | Sale | WYSZOMIERSKI JACK L | director | 3,925 0.0016% | $50.55 | $198,409 | +11.52% | |
| 2026-06-01 | Sale | Eckhardt Sue Gail | director | 9,812 0.0039% | $50.14 | $491,974 | +11.52% | |
| 2026-05-26 | Sale | Aftab Dana | EVP, Research and Development | 43,451 0.0174% | $50.35 | $2.19M | +12.01% | |
| 2026-05-20 | Sale | Haley Patrick J. | EVP, Commercial | 32,110 0.0128% | $49.81 | $1.6M | +12.06% | |
| 2026-05-18 | Sale | Senner Christopher J. | EVP and CFO | 34,901 0.0139% | $50.00 | $1.75M | +12.06% | |
| 2026-05-18 | Sale | Hefti Brenda | SVP and General Counsel | 6,625 0.0027% | $50.21 | $332,641 | +12.06% | |
| 2026-05-07 | Sale | POSTE GEORGE | director | 60,000 0.0234% | $45.71 | $2.74M | +20.46% | |
| 2026-05-07 | Sale | Freire Maria C | director | 20,634 0.0081% | $46.00 | $949,164 | +20.46% | |
| 2026-05-07 | Sale | Beckerle Mary C | director | 7,712 0.0032% | $48.45 | $373,646 | +20.46% | |
| 2026-02-24 | Sale | Aftab Dana | EVP, Research and Development | 47,918 0.0176% | $44.50 | $2.13M | +17.41% | |
| 2026-02-19 | Sale | Aftab Dana | EVP, Research and Development | 29,873 0.0111% | $44.35 | $1.32M | +19.96% | |
| 2026-02-18 | Sale | WYSZOMIERSKI JACK L | director | 99,574 0.0368% | $44.01 | $4.38M | +19.09% | |
| 2026-02-18 | Sale | Hefti Brenda | SVP and General Counsel | 18,669 0.0069% | $44.01 | $821,623 | +19.09% | |
| 2026-02-18 | Sale | Smith Julie | director | 64,117 0.0239% | $44.44 | $2.85M | +19.09% | |
| 2026-02-17 | Sale | Senner Christopher J. | EVP and CFO | 30,617 0.0113% | $43.67 | $1.34M | +20.04% | |
| 2026-02-17 | Sale | Haley Patrick J. | EVP, Commercial | 67,814 0.025% | $43.52 | $2.95M | +20.04% | |
| 2026-02-17 | Sale | Smith Julie | director | 42,422 0.0156% | $43.33 | $1.84M | +20.04% | |
| 2026-02-13 | Sale | Senner Christopher J. | EVP and CFO | 34,278 0.0125% | $43.00 | $1.47M | +20.38% | |
| 2026-02-13 | Sale | Oliver Bob | director | 30,250 0.0113% | $43.81 | $1.33M | +20.38% |
| JOHNSON DAVID EDWARD | director | 1553262 0.618% | $112.32M | 5 | 1 | +39.52% |
| PAPADOPOULOS STELIOS | director | 1189228 0.4731% | $85.99M | 2 | 13 | +117.05% |
| SCANGOS GEORGE A | director | 714717 0.2843% | $51.68M | 1 | 243 | +51.69% |
| Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | 614078 0.2443% | $44.4M | 1 | 37 | +9.5% |
| WILLSEY LANCE | 424415 0.1689% | $30.69M | 12 | 12 | +142.31% | |
| MORRISSEY MICHAEL | President and CEO | 85985 0.0342% | $6.22M | 1 | 60 | +201.22% |
| MARCHESI VINCENT T | director | 66115 0.0263% | $4.78M | 13 | 13 | +2.14% |
| KARBE FRANK | EVP & CFO | 60110 0.0239% | $4.35M | 3 | 0 | +92.47% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 363 | +52.76% | 27M | +10.61% |
| Decreased Positions | 303 | -44.04% | 18M | -7.32% |
| New Positions | 123 | New | 4M | New |
| Sold Out Positions | 59 | Sold Out | 1M | Sold Out |
| Total Postitions | 748 | +8.72% | 261M | +3.3% |
| Blackrock, Inc. | $1.28M | 10.96% | 29.37M | -692,050 | -2.3% | 2025-09-30 |
| Vanguard Group Inc | $1.14M | 9.73% | 26.06M | -1M | -5.11% | 2025-09-30 |
| Farallon Capital Management Llc | $849,875.00 | 7.28% | 19.5M | +3M | +21.61% | 2025-09-30 |
| Renaissance Technologies Llc | $673,715.00 | 5.77% | 15.46M | -360,499 | -2.28% | 2025-09-30 |
| State Street Corp | $484,384.00 | 4.15% | 11.11M | -269,846 | -2.37% | 2025-09-30 |
| Aqr Capital Management Llc | $400,124.00 | 3.43% | 9.18M | +2M | +20.71% | 2025-09-30 |
| Fuller & Thaler Asset Management, Inc. | $362,620.00 | 3.11% | 8.32M | -454,778 | -5.18% | 2025-09-30 |
| Lsv Asset Management | $338,557.00 | 2.9% | 7.77M | -51,820 | -0.66% | 2025-09-30 |
| Geode Capital Management, Llc | $334,300.00 | 2.86% | 7.67M | +225,490 | +3.03% | 2025-09-30 |
| Invesco Ltd. | $259,760.00 | 2.22% | 5.96M | +394,897 | +7.09% | 2025-09-30 |